(Q37655886)

21 August 2017

1 reference

title

The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia (English)

1 reference

21 August 2017

1 reference

1 reference

2

Jude Fitzgibbon

1 reference

21 August 2017

Carolyn Owen

1

1 reference

PubMed ID

20013787

21 August 2017

Peter Paschka

series ordinal

3

1 reference

21 August 2017

1 March 2010

1 reference

21 August 2017

Hematological Oncology

1 reference

21 August 2017

28

1 reference

21 August 2017

1

1 reference

21 August 2017

13-19

1 reference

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

21 August 2017

1 reference

7 January 2021

Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia

1 reference

7 January 2021

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

1 reference

7 January 2021

Impact of new prognostic markers in treatment decisions in acute myeloid leukemia

1 reference

7 January 2021

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

1 reference

7 January 2021

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

1 reference

7 January 2021

Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia

1 reference

7 January 2021

Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia

1 reference

7 January 2021

Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia

1 reference

7 January 2021

Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.

1 reference

7 January 2021

Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

1 reference

7 January 2021

Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer

1 reference

7 January 2021

Recurring mutations found by sequencing an acute myeloid leukemia genome

1 reference

7 January 2021

Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour

1 reference

7 January 2021

Wilms' tumour: connecting tumorigenesis and organ development in the kidney

1 reference

7 January 2021

A tumor suppressor and oncogene: the WT1 story.

1 reference

7 January 2021

Antiapoptotic function of 17AA(+)WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway

1 reference

7 January 2021

WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins.

1 reference

7 January 2021

The Wilms tumour suppressor protein WT1 (+KTS isoform) binds alpha-actinin 1 mRNA via its zinc-finger domain.

1 reference

7 January 2021

High expression of WT1 gene in acute myeloid leukemias with more predominant WT1+17AA isoforms at relapse.

1 reference

7 January 2021

N-terminally truncated WT1 protein with oncogenic properties overexpressed in leukemia

1 reference

7 January 2021

The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis

1 reference

7 January 2021

WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study

1 reference

7 January 2021

Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia

1 reference

7 January 2021

High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.

1 reference

7 January 2021

Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia

1 reference

7 January 2021

Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy

1 reference

7 January 2021

Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients

1 reference

7 January 2021

Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals.

1 reference

7 January 2021

Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.

1 reference

7 January 2021

Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia

1 reference

7 January 2021

Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia.

1 reference

7 January 2021

Multiplex real-time RT-PCR for prospective evaluation of WT1 and fusion gene transcripts in newly diagnosed de novo acute myeloid leukemia

1 reference

7 January 2021

WT1 expression at diagnosis does not predict survival in pediatric AML: a report from the Children's Oncology Group

1 reference

7 January 2021

Wilms' tumour gene (wt1) expression at diagnosis has no prognostic relevance in childhood acute lymphoblastic leukaemia treated by an intensive chemotherapy protocol

1 reference

7 January 2021

Wilms' tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome.

1 reference

7 January 2021

Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.

1 reference

7 January 2021

WT1 mutations in T-ALL

1 reference

7 January 2021

Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression

1 reference

7 January 2021

Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.

1 reference

7 January 2021

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.

1 reference

7 January 2021

The Wilms tumour (WT1) gene is mutated in a secondary leukaemia in a WAGR patient

1 reference

7 January 2021

Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias

1 reference

7 January 2021

Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML.

1 reference

7 January 2021

Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party

1 reference

7 January 2021

Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study

1 reference

7 January 2021

Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group

1 reference

7 January 2021

Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association

1 reference

7 January 2021

Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia

1 reference

7 January 2021

Acute myeloid leukemia bearing t(7;11)(p15;p15) is a distinct cytogenetic entity with poor outcome and a distinct mutation profile: comparative analysis of 493 adult patients.

1 reference

7 January 2021

Prevalence of WT1 mutations in a large cohort of patients with steroid-resistant and steroid-sensitive nephrotic syndrome.

1 reference

7 January 2021

Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.

1 reference

7 January 2021

Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. European Working Group on MDS in Childhood (EWOG-MDS)

1 reference

7 January 2021

A zinc finger truncation of murine WT1 results in the characteristic urogenital abnormalities of Denys-Drash syndrome

1 reference

7 January 2021

The Wt1+/R394W mouse displays glomerulosclerosis and early-onset renal failure characteristic of human Denys-Drash syndrome

1 reference

7 January 2021

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia

1 reference

7 January 2021

Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study.

1 reference

7 January 2021

Wilms' tumor 1 mutation accumulated during therapy in acute myeloid leukemia: biological and clinical implications

1 reference

7 January 2021

Identifiers

DOI

10.1002/HON.931

1 reference

21 August 2017

1 reference

PubMed ID

20013787